The University of Cambridge, in partnership with AstraZeneca, offers a funded PhD studentship to explore proteasome-targeting tools and novel Midnolin-based degrader approaches for targeted protein degradation (TPD). Supervised by Dr Catherine Lindon and a team from Cambridge and AstraZeneca, the project seeks motivated students with interests in cell biology and biochemistry.
Funding covers stipend and Home fees for four years; overseas applicants may require additional funding.
#J-18808-Ljbffr
PhD in Targeted Protein Degradation Tools in Cambridge employer: University of Cambridge
The University of Cambridge offers a dynamic and collaborative work environment, particularly within the Department of Oncology, where you will play a pivotal role in advancing cancer research. With a strong emphasis on employee growth, you will have access to professional development opportunities and the chance to work alongside leading experts in the field. The university's commitment to innovation and excellence ensures that your contributions will have a meaningful impact on clinical care and research outcomes.
